BAX:NYE-Baxter International Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 40.13

Change

-0.10 (-0.25)%

Market Cap

USD 25.26B

Volume

2.01M

Analyst Target

USD 96.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.57 (+0.24%)

USD 68.37B
ALC Alcon AG

+0.56 (+0.70%)

USD 39.66B
HYB New America High Income Closed..

+0.04 (+0.56%)

USD 35.93B
RMD ResMed Inc

-0.78 (-0.36%)

USD 27.76B
WST West Pharmaceutical Services I..

+1.81 (+0.49%)

USD 27.24B
TFX Teleflex Incorporated

+0.56 (+0.28%)

USD 10.10B
ATR AptarGroup Inc

+0.68 (+0.46%)

USD 9.88B
STVN Stevanato Group SpA

+0.97 (+3.64%)

USD 7.29B
BLCO Bausch + Lomb Corp

+0.46 (+3.19%)

USD 5.08B
HAE Haemonetics Corporation

-0.18 (-0.19%)

USD 4.30B

ETFs Containing BAX

PBI Pitney Bowes Inc 0.00 % 0.79 %

-0.06 (-1.13%)

USD 0.70B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.80% 78% C+ 64% D
Dividend Return 0.75% 75% C 39% F
Total Return 4.55% 78% C+ 63% D
Trailing 12 Months  
Capital Gain -15.83% 28% F 15% F
Dividend Return 2.43% 78% C+ 36% F
Total Return -13.40% 33% F 14% F
Trailing 5 Years  
Capital Gain -47.32% 9% A- 12% F
Dividend Return 6.96% 43% F 23% F
Total Return -40.36% 9% A- 12% F
Average Annual (5 Year Horizon)  
Capital Gain -14.75% 11% F 6% D-
Dividend Return -13.26% 11% F 6% D-
Total Return 1.49% 78% C+ 36% F
Risk Return Profile  
Volatility (Standard Deviation) 18.20% 83% B 60% D-
Risk Adjusted Return -72.85% 6% D- 4% F
Market Capitalization 25.26B 72% C 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.30 20% 7%
Price/Book Ratio 2.44 67% 35%
Price / Cash Flow Ratio 12.08 71% 31%
Price/Free Cash Flow Ratio 18.97 41% 16%
Management Effectiveness  
Return on Equity -0.96% 41% 27%
Return on Invested Capital 1.90% 47% 30%
Return on Assets 3.34% 61% 59%
Debt to Equity Ratio 132.47% 8% 26%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector